The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non–type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments.

新描述的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 是造成大流行（2019 年冠状病毒病 [COVID-19]）的原因。现在已经明确，某些合并症定义为高风险患者。它们包括高血压、糖尿病和冠状动脉疾病。相比之下，支气管哮喘的背景存在争议，并且显示出明显的地区差异。由于哮喘是全世界最常见的慢性炎症性肺病，而 SARS-CoV-2 主要影响上呼吸道和下呼吸道，导致明显的炎症，因此出现了哮喘与 SARS-CoV-2/COVID 之间可能存在的临床和病理生理学关联的问题。 19. 在这里，我们分析了 COVID-19 患者中哮喘的全球流行病学，并提出了这样的概念：患有不同哮喘内型（2 型哮喘与非 2 型哮喘）的患者在 SARS-CoV 方面表现出不同的风险状况。 2 感染、COVID-19 的发展以及进展为严重的 COVID-19 结果。这一概念可能对未来的 COVID-19 诊断和免疫疗法的发展产生重要影响。